Genomic profiling of inflammatory breast cancer: a review.
暂无分享,去创建一个
Daniel Birnbaum | Pascal Finetti | François Bertucci | F. Bertucci | D. Birnbaum | P. V. van Dam | P. Finetti | P. Vermeulen | L. Dirix | S. V. van Laere | P. Viens | Peter Vermeulen | Luc Dirix | Steven Van Laere | Patrice Viens | Peter Van Dam
[1] F. Bertucci,et al. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] K. Baggerly,et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers , 2013, Breast Cancer Research.
[3] Rosette Lidereau,et al. miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness , 2013, International journal of cancer.
[4] Yu Cao,et al. Inflammatory breast cancer (IBC): clues for targeted therapies , 2013, Breast Cancer Research and Treatment.
[5] T. Ideker,et al. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. , 2013, Journal of proteome research.
[6] P. Vermeulen,et al. Modeling and characterization of inflammatory breast cancer emboli grown in vitro , 2013, International journal of cancer.
[7] F. Bertucci,et al. Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets , 2013, Clinical Cancer Research.
[8] S. Krishnamurthy,et al. Genomic Profiling of Pre-Clinical Models of Inflammatory Breast Cancer Identifies a Signature of Epithelial Plasticity and Suppression of TGFò Signaling , 2012 .
[9] T. Delozier,et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.
[10] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[11] K. Aird,et al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration , 2011, British Journal of Cancer.
[12] S. Merajver,et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Daniel Birnbaum,et al. High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.
[14] Y. Ye,et al. The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction , 2011, Oncogene.
[15] Patrick Pauwels,et al. Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.
[16] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[17] I. Van der Auwera,et al. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype , 2010, British Journal of Cancer.
[18] M. Desilvio,et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Bertucci,et al. Gene expression profiling of inflammatory breast cancer , 2010, Cancer.
[20] E. Sahai,et al. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. , 2010, Cancer research.
[21] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[22] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Annuska M. Glas,et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.
[24] W. Grizzle,et al. Dual effects of TGF-β on ERα-mediated estrogenic transcriptional activity in breast cancer , 2009, Molecular Cancer.
[25] Erik Sahai,et al. Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.
[26] P. Levine,et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.
[27] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[28] John N Weinstein,et al. A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.
[29] F. Bertucci,et al. Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.
[30] Selin Carkaci,et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.
[31] Rosette Lidereau,et al. BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer , 2008 .
[32] E. van Marck,et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.
[33] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Hilsenbeck,et al. Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.
[35] E. van Marck,et al. Nuclear Factor-κB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-κB DNA-Binding , 2006, Clinical Cancer Research.
[36] Andrea Bild,et al. Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.
[37] M. Cassone,et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis , 2005 .
[38] Daniel Birnbaum,et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.
[39] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] F. Bertucci,et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.
[41] Rosette Lidereau,et al. Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.
[42] F. Bertucci,et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.
[43] Josef Gotzmann,et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. , 2004, Mutation research.
[44] M. Espié,et al. Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] E. van Marck,et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.
[46] M. Espié,et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer , 2002, International journal of cancer.
[47] S. Merajver,et al. Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.
[48] L. Zelek,et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers , 2000, Oncogene.
[49] S. Merajver,et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] G. Hortobagyi,et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.
[51] Z. Baloch,et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.
[52] B. Asselain,et al. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis , 1987, Cancer.